Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers
Open Access
- 1 February 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 73 (4) , 543-548
- https://doi.org/10.1038/bjc.1996.94
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Arimidex : A potent and selective fourth-generation aromatase inhibitorBreast Cancer Research and Treatment, 1994
- Experience with aromatase inhibitors in the treatment of advanced breast cancerCancer Treatment Reviews, 1993
- The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.1993
- Endocrine therapy for advanced breast cancer: A reviewBreast Cancer Research and Treatment, 1992
- Clinical use of aromatase inhibitors in human breast carcinomaThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase InhibitorJournal of Clinical Endocrinology & Metabolism, 1991
- Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedioneCancer Chemotherapy and Pharmacology, 1990
- Aromatase inhibitors in the treatment of advanced breast cancerCancer Treatment Reviews, 1989
- Aminoglutethimide dose and hormone suppression in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983